Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Karim Iskander"'
Autor:
Philippe Moreau, Keith A. Stewart, Meletios Dimopoulos, David Siegel, Thierry Facon, James Berenson, Noopur Raje, Jesus G. Berdeja, Robert Z. Orlowski, Hui Yang, Haijun Ma, Zandra Klippel, Anita Zahlten‐Kumeli, Khalid Mezzi, Karim Iskander, Maria‐Victoria Mateos
Publikováno v:
Cancer Medicine, Vol 9, Iss 9, Pp 2989-2996 (2020)
Abstract Combination of carfilzomib with dexamethasone (Kd) is approved for use in relapsed and/or refractory multiple myeloma (RRMM), with carfilzomib administered twice weekly at 56 mg/m2 (Kd56 BIW) or once weekly at 70 mg/m2 (Kd70 QW). Post hoc cr
Externí odkaz:
https://doaj.org/article/228d0e9245d94238b5930f7eee8ce724
Autor:
Ola Landgren, Dickran Kazandjian, Murielle Roussel, Jagoda Jasielec, Dominik Dytfeld, Aparna Anderson, Tara A. Kervin, Karim Iskander, Ian McFadden, Andrzej J. Jakubowiak
Publikováno v:
Leukemialymphoma. 63(10)
Pooled analyses of four single-arm phase 1 and 2 studies (NCT01816971, NCT02405364, NCT01029054, NCT01402284) investigated the clinical effectiveness of carfilzomib-lenalidomide-dexamethasone (KRd) in newly diagnosed multiple myeloma (NDMM). Patients
Autor:
Maria-Elisabeth Goebeler, Nicholas J. Morley, Ralf C. Bargou, Alicia Zhang, Janet Franklin, Luke Coyle, Karim Iskander, Andreas Viardot, Georg Hess, Giuseppe Gritti, David Cohan
Publikováno v:
Leukemia & Lymphoma. 61:2767-2770
Despite advances in standards of care, the prognosis of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains poor. In these patients, 50–74% fail to respond to next line therapy,...
Autor:
Jesus G. Berdeja, Noopur Raje, Anita Zahlten-Kumeli, Thierry Facon, Haijun Ma, Keith Stewart, David S. Siegel, Zandra Klippel, Meletios A. Dimopoulos, Hui Yang, Khalid Mezzi, Maria-Victoria Mateos, James R. Berenson, Robert Z. Orlowski, Karim Iskander, Philippe Moreau
Publikováno v:
Cancer Medicine. 9:2989-2996
Combination of carfilzomib with dexamethasone (Kd) is approved for use in relapsed and/or refractory multiple myeloma (RRMM), with carfilzomib administered twice weekly at 56 mg/m2 (Kd56 BIW) or once weekly at 70 mg/m2 (Kd70 QW). Post hoc cross-trial
Autor:
Amy S. Kimball, Ralph V. Boccia, Darrell White, Ruben Niesvizky, Meletios A. Dimopoulos, Zhao Yang, Khalid Mezzi, Karim Iskander, Heinz Ludwig, David S. Siegel
Publikováno v:
Blood. 133:147-155
In ENDEAVOR, carfilzomib (56 mg/m2) and dexamethasone (Kd56) demonstrated longer progression-free survival (PFS) over bortezomib and dexamethasone (Vd) in patients with relapsed/refractory multiple myeloma (RRMM). Here we evaluated Kd56 vs Vd by base
Publikováno v:
Cancer Research. 82:1845-1845
Autor:
Robert Z. Orlowski, Marion Subklewe, Karim Iskander, Hagop M. Kantarjian, Gerhard Zugmaier, Hossein Borghaei, Gail J. Roboz, Hermann Einsele, Peter Kufer
Publikováno v:
CancerReferences. 126(14)
Immuno-oncology therapies engage the immune system to treat cancer. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facil
Autor:
Roman Hájek, Philippe Moreau, Ajai Chari, Alexander R. Lyon, Daniel J. Lenihan, Mei Huang, John D. Groarke, Karim Iskander, George N. Batty, Sunhee Ro, Jose Banchs, Joerg Herrmann, A. Keith Stewart, Stuart D. Russell
Publikováno v:
Blood Advances. 2:1633-1644
Carfilzomib is a selective proteasome inhibitor approved for the treatment of relapsed and/or refractory multiple myeloma (RRMM). It has significantly improved outcomes, including overall survival (OS), and shown superiority vs standard treatment wit
Autor:
Babatunde Adedokun, Faraz Zaman, Brent L. Wood, Gail J. Roboz, Elias Jabbour, Michael J. Borowitz, Ehab Elkhouly, Kelly Velasco, Juliana E. Hidalgo-Lopez, Aaron C Logan, Karim Iskander
Publikováno v:
Blood. 138:4478-4478
Background: MRD testing in BCP-ALL is critical for appropriate patient management, but little is known regarding sample acquisition and testing heterogeneity across clinical practice settings. These factors may impact the quality and reliability of M
Autor:
Meletios-Athanasios Dimopoulos, Joshua Richter, Karim Iskander, Meral Beksac, Katja Weisel, Ajai Chari, Akeem Yusuf, Joseph Mikhael, Franziska Dirnberger, Xavier Leleu
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S142
Background With increasing utilization of immunomodulatory agents (particularly lenalidomide) for the management of newly diagnosed multiple myeloma, there is an emerging need for efficacious lenalidomide-free options at relapse. In the CANDOR trial,